Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures

Cancer Gene Therapy

Volumn 17, Issue 4, 2010, Pages 223-234

  Valyi Nagy, K ^a   Dosa, S ^a   Kovacs, S K ^a   Bacsa, S ^a   Voros, A ^a   Shukla, D ^a   Folberg, R ^a   Valyi Nagy, T ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Extracellular matrix; Herpes simplex virus; Matrigel; Oncolytic therapy; Quiescence; Vasculogenic mimicry

Indexed keywords

ONCOLYTIC VIRUS;

ARTICLE; CANCER CELL CULTURE; CULTURE TECHNIQUE; EXTRACELLULAR MATRIX; HERPES SIMPLEX VIRUS 1; MELANOMA CELL; MULTICELLULAR SPHEROID; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; THREE DIMENSIONAL CULTURE; TWO DIMENSIONAL CULTURE; UVEA MELANOMA; VIRUS ENTRY; VIRUS INFECTION; VIRUS REPLICATION;

CELL CULTURE TECHNIQUES; COLLAGEN; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; EXTRACELLULAR MATRIX; HERPESVIRUS 1, HUMAN; HUMANS; LAMININ; MELANOMA; ONCOLYTIC VIROTHERAPY; PROTEOGLYCANS; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 77949654118     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.73     Document Type: Article

References (46)

1. Guo SZ, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231.
2. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008; 15: 877-884.
3. Latchman DS. Herpes simplex virus-based vectors for the treatment of cancer and neurodegenerative disease. Curr Opin Mol Ther 2005; 7: 415-418.
4. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525-526.
5. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006; 13: 975-992.
6. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
7. Chiocca EA. The host response to cancer virotherapy. Curr Opin Mol Ther 2008; 10: 38-45.
8. Benecia F, Courreges MC, Fraser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008; 7: 1194-1205.
9. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Curr Cancer Drug Targets 2007; 7: 149-155.
10. Miller CG, Fraser NW. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 2003; 7: 741-747.
11. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-393.
12. Guzman G, Oh SD, Shukla D, Valyi-Nagy T. Nectin-1 expression in the normal and neoplastic human female gynecologic tract. Arch Pathol Lab Med 2006; 130: 1191-1195.
13. Guzman G, Oh SD, Shukla D, Engelhard HH, Valyi-Nagy T. Expression of entry receptor nectin-1 of Herpes simplex virus 1 and/or Herpes simplex virus 2 in normal and neoplastic human nervous system tissues. Acta Virol 2006; 50: 59-66.
14. Kolodkin-Gal D, Zamir G, Edden Y, Pikarsky E, Pikarsky A, Haim H et al. Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix. J Virol 2008; 82: 999-1010.
15. McKie TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509-2513.
16. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficiency of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795-3802.
17. Rueger MA, Winkeler A, Miletic H, Kaestle C, Richter R, Schneider G et al. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2005; 12: 588-596.
18. Yu Z, Adusumilli PS, Eisenberg DP, Darr E, Ghossein RA, Li S et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 2007; 15: 103-113.
19. Yun CO. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 2008; 10: 356-361.
20. Abbott A. Biology's new dimension. Nature 2003; 424: 870-872.
21. Friedrich MJ. Studying cancer in 3 dimensions. JAMA 2003; 290: 1977-1979.
22. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005; 204: 522-531.
23. Smalley KS, Lioni M, Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In vitro Cell Dev Biol Anim 2006; 42: 242-247.
24. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005; 15: 342-352.
25. Xu F, Burg KJL. Three-dimensional polymeric systems for cancer cell studies. Cytotechnology 2007; 54: 135-143.
26. Schmeichel KL, Bissell MJ. Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 2003; 116: 2377-2388.
27. Schmidmaier R, Baumann P. Anti-adhesion evolves to a promising therapeutic concept in oncology. Curr Med Chem 2008; 15: 978-990.
28. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998; 95: 14821-14826.
29. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137: 231-245.
30. Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 2002; 111: 923-925.
31. Vescio RA, Redfern CH, Nelso TJ, Udoretz S, Stern PH, Hoffman RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 1987; 84: 5029-5033.
32. Shimony N, Gorodetsky R, Marx G, Gal D, Rivkin R, Ben-Ari A et al. Fibrin microbeads (FMB) as a 3D platform for kidney gene and cell therapy. Kidney Int 2006; 69: 625-633.
33. Valyi-Nagy K, Folberg R, Valyi-Nagy T, Maniotis AJ. Susceptibility of uveal melanoma to herpes simplex virus type 1: the role of tumor invasiveness, the extracellular matrix and chromatin sequestration. Exp Eye Res 2007; 84: 991-1000.
34. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156: 361-381.
35. Folberg R, Arbieva Z, Moses J, Hayee A, Sandal T, Kadkol S et al. Tumor cell plasticity in uveal melanoma\micro-environment directed dampening of the invasive and meta-static genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol 2006; 169: 1376-1389.
36. Folberg R, Leach L, Valyi-Nagy K, Lin AY, Apushkin MA, Ai Z et al. Modeling the behavior of uveal melanoma in the liver. Invest Ophthalmol Vis Sci 2007; 48: 2967-2974.
37. Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS 2004; 112: 508-525.
38. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
39. Maniotis AJ, Valyi-Nagy K, Karavitis J, Moses J, Boddipali JV, Wang Y et al. Chromatin organization measured by Alu I restriction enzyme changes with malignancy and is regulated by the extracellular matrix and the cytoskeleton. Am J Pathol 2005; 166: 1187-1203.
40. Desai P, Pearson S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol 1998; 72: 7563-7568.
41. Akhtar J, Tiwari V, Oh M, Kovacs M, Jani A, Kovacs SK et al. HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium. Invest Ophthalmol Vis Sci 2008; 49: 4026-4035.
42. Folberg R, Kadkol S, Frenkel S, Valyi-Nagy K, Jager MJ, Pe'er J et al. Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci 2008; 49: 4697-4701.
43. Weeks BS, Ramchandran RS, Hopkins JJ, Friedman HM. Herpes simplex virus type-1 and-2 pathogenesis is restricted by the epidermal basement membrane. Arch Virol 2000; 145: 385-396.
44. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F et al. Beta4 integrin dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002; 2: 205-216.
45. Preston CM. Repression of viral transcription during herpes simplex virus latency. J Gen Virol 2000; 81: 1-19.
46. Valyi-Nagy T, Shukla D, Engelhard HH, Kavouras J, Scanlan P. Latency strategies of alphaherpesviruses: herpes simplex virus and varicella-zoster virus latency in neurons. In: Minarovits J, Gonczol E, Valyi-Nagy T (eds). Latency Strategies of Herpesviruses. Springer: New York, 2007. pp 1-36.